Table 1 Participant demographics
Characteristic | Group 1 (n = 19) | Group 2 (n = 16) | Group 3 (n = 16) | Group 4 (n = 18) |
|---|---|---|---|---|
Participant demographics | Â | Â | Â | Â |
Age (years) | 52.04 (11.7) | 50.27 (8.48) | 55.65 (9.49) | 55.59 (6.69) |
Time since diagnosis (years) | 3.39 (0.90) | 2.69 (0.92) | 3.19 (0.85) | 3.14 (1.22) |
Menopausal status* | Â | Â | Â | Â |
Premenopausal | 11 (58%) | 11 (69%) | 8 (50%) | 8 (44%) |
Postmenopausal | 8 (42%) | 5 (31%) | 8 (50%) | 10 (56%) |
Marital status | Â | Â | Â | Â |
Married | 16 (84%) | 10 (63%) | 11 (69%) | 11 (61%) |
Single | 3 (16%) | 6 (37%) | 5 (31%) | 5 (39%) |
Smoking history | Â | Â | Â | Â |
Current smoker | 1 (5%) | 9 (56%) | 2 (13%) | 6 (33%) |
Cancer details | Â | Â | Â | Â |
Cancer stage | Â | Â | Â | Â |
I | 6 (32%) | 4 (25%) | 5 (31%) | 4 (22%) |
II | 9 (47%) | 9 (56%) | 8 (50%) | 10 (56%) |
III | 4 (21%) | 3 (19%) | 3 (19%) | 4 (22%) |
Estrogen receptor positive | 14 (74%) | 14 (88%) | 14 (88%) | 14 (78%) |
Surgery | Â | Â | Â | Â |
Wide local excision | 9 (47%) | 5 (31%) | 10 (63%) | 7 (39%) |
Mastectomy | 10 (53%) | 11 (69%) | 6 (38%) | 11 (61%) |
Axillary clearance | 7 (37%) | 9 (38%) | 4 (25%) | 10 (56%) |
Chemotherapy | 17 (90) | 14 (88%) | 13 (81%) | 16 (89%) |
Radiotherapy | 15 (79) | 11 (69%) | 14 (88%) | 16 (89%) |
Hormone therapy | Â | Â | Â | Â |
Tamoxifen | 9 (47%) | 7 (44%) | 12 (75%) | 7 (39%) |
Aromatase inhibitor | 5 (26%) | 6 (38%) | 2 (13%) | 7 (39%) |
Biological therapy | Â | Â | Â | Â |
Herceptin | 3 (16%) | 2 (13%) | 1 (6%) | 2 (11%) |